Preoperative CA 15‐3 concentrations predict outcome of patients with breast carcinoma

Shering, S. G.; Sherry, F.; McDermott, Enda; O’Higgins, N.; Duffy, Michael J.

doi:10.1002/(sici)1097-0142(19981215)83:12<2521::aid-cncr17>3.3.co;2-1

Cited by 18 publications

(25 citation statements)

References 16 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As we determined both markers, CEA and CA 15-3, it is difficult to compare our study with the two other relevant studies of Gion and Shering (Gion et al, 1991;Shering et al, 1998). Although Gion found, in accordance to us, that pre-operative serum levels of CA 15-3 had no prognostic relevance in multivariate analysis, the number of patients and the unknown number of relapse and death from disease is probably too small to give reliable results.…”

Section: Discussionmentioning

confidence: 54%

“…In contrast Shering et al (1998) reported on a high number of patients and found a prognostic relevance for pre-operative CA 15-3 values. The prognostic relevance of a single factor in multivariate analysis depends on which and how other factors are included in the model.…”

Section: Discussionmentioning

confidence: 88%

“…To our knowledge, there is no multivariate analysis on CEA in serum, only a few studies performed multivariate analyses on CEA in breast cancer tissue (Esteban et al, 1994;Sundblad et al, 1996). Among the two multivariate analyses of CA 15-3 in serum at the time of diagnosis of breast cancer (Gion et al, 1991;Shering et al, 1998), only Shering had a sufficiently high number of patients. To date, no study has tested both tumour markers CEA and CA 15-3 for independent prognostic value at the time of primary intervention in breast cancer patients.…”

Section: Discussionmentioning

confidence: 99%

“…Circulating tumour markers as Carcinoembryonic Antigen (CEA) and Cancer Antigen 15-3 (CA 15-3) have become well established diagnostic tools as fast, non-invasive, reproducible and quantitative parameters in follow-up care and monitoring therapy of breast cancer patients. However, the potential role of these factors in prognosis has only been studied in a few investigations, which came to inconsistent conclusions (Tondini et al, 1989;Lamerz et al, 1993;Shering et al, 1998). The only multivariate analysis based on a large number of patients (Shering et al, 1998) investigated CA 15-3 alone.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Serum CEA and CA 15-3 as prognostic factors in primary breast cancer

et al. 2002

View full text Add to dashboard Cite

In the present study, we investigated the association of the serum levels of the tumour markers carcinoembryonic antigen and cancer antigen 15-3 with disease free survival and death from disease in 1046 women with breast cancer without metastases at the time of primary diagnosis in relation to age and the established prognostic factors tumour size, lymph node status, histological grading and hormone receptor status. We found that elevated pre-operative serum marker values were correlated with early relapse (cancer antigen 15-3; P=0.0003) and death from disease (carcinoembryonic antigen, cancer antigen 15-3; P=0.0001 both) in univariate analyses. By comparing pre-and post-operative values we found a decline in values post-surgery. In those patients where marker levels of carcinoembryonic antigen decreased more than 33%, a significantly higher risk for relapse and death from disease (both P=0.0001) in univariate analyses was observed. In multivariate analysis this decrease of carcinoembryonic antigen proved to be an independent prognostic factor. The results for cancer antigen 15-3 were comparable to carcinoembryonic antigen in univariate analyses but showed no significance in multivariate analysis. In this study the post-operative decrease of the serum tumour marker carcinoembryonic antigen was a strong independent prognostic factor for disease free survival and death from disease in breast cancer patients.

show abstract

Section: Discussionmentioning

confidence: 54%

Section: Discussionmentioning

confidence: 88%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Serum CEA and CA 15-3 as prognostic factors in primary breast cancer

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Much less has been written about the prognostic value of tumour markers. Correlations between raised preoperative levels of CA15.3 and CEA with poorer outcome have been reported (Molina et al, 1998;Shering et al, 1998;Ebeling et al, 1999;McLaughlin et al, 2000;Canizares et al, 2001). To our knowledge, the prognostic significance of an elevated CA15.3 and CEA in patients presenting with bone metastases has not been previously described.…”

Section: Discussionmentioning

confidence: 86%

Bone metastases from breast carcinoma: histopathological – radiological correlations and prognostic features

et al. 2003

View full text Add to dashboard Cite

The aim of this study was to identify factors that may be associated with the development of bone metastases in patients with metastatic breast carcinoma and to see if any of these factors had a bearing on subsequent survival. In total, 492 patients presented to the Nottingham City Hospital with metastatic breast carcinoma between July 1997 and December 2001. Of these, 267 patients had bone metastases at presentation with metastatic disease, 91 patients in this group had bone as their only site of metastatic disease. Sites of first presentation of metastatic disease were prospectively recorded, as were histological features of the primary tumour (tumour type, histological grade, lymph node stage, tumour size and oestrogen receptor (ER) status). The radiological features of the bone metastases, the metastasis-free interval and serological tumour marker levels at presentation with metastases were all recorded. There was a significant association between the development of bone metastases and lower grade tumours (P ¼ 0.019), ER-positive tumours (Po0.0001) and the lymph node stage of the primary tumour (P ¼ 0.047). A multivariate analysis found that metastasis-free interval, additional sites of metastatic disease other than bone, ER status and serological tumour marker levels all independently contributed to survival from time of presentation with bone metastases. British Journal of Cancer (2003) The survival of patients with metastases is variable ranging from a matter of months to many years. The ability to predict prognosis and response to treatment has a considerable impact on patient management. It is well established that oestrogen receptor (ER) status and site of presentation of metastatic disease have the greatest impact on patient survival, with additional contributions made by patient age, disease-free interval and histological grade.Bone is the most common site of metastases in patients with breast carcinoma and so patients with bone metastases make up the largest single group of patients presenting with metastatic disease. It has previously been reported that 20% of patients with bone metastases survive for more than 5 years, which emphasises the wide variation in survival seen in this group of patients (Coleman et al, 1987). The aim of this study was to identify factors that may be associated with the development of bone metastases and to see if any of these factors had any bearing on subsequent survival.We have assessed traditional factors such as ER status, histological grade, lymph node stage and size of the primary tumour, patient age, metastasis-free interval and the presence of metastases at sites other than bone. We have examined the radiological appearance of the bone metastases and looked for associations with the histological features of the tumour and patient survival. In common with other centres, we increasingly use serological tumour markers in the diagnosis and monitoring of patients with metastatic breast carcinoma. The prognostic significance of elevated tumour markers at presentation ...

show abstract

G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting

Briasoulis

Andreopoulou

Tolis

et al. 2001

Cancer

View full text Add to dashboard Cite

BACKGROUND Cancer antigen 15‐3 (CA 15‐3), a circulating marker that determines secreted products of the polymorphic MUC1 gene, has been established as a convenient tool for monitoring breast carcinoma patients. METHODS The authors investigated alterations of soluble CA 15‐3 in 57 postoperative breast carcinoma patients while they were receiving intensified adjuvant chemotherapy with granulocyte colony stimulating factor (G‐CSF) support; 26 patients had American Joint Committee on Cancer (AJCC) Stage II, and 31 patients had AJCC Stage III breast carcinoma. Serial CA 15‐3 values recorded thoughout the treatment were compared with baseline values, analyzed for correlation with hematologic and biochemical parameters, and compared with clinicopathologic characteristics and patient outcome. At a median follow‐up time of 32 months, 47 of these patients remained relapse‐free. RESULTS A twofold increase of CA 15‐3 was detected at the end of the second week of treatment, remained significantly elevated in most patients at above the cutoff level of 30 U/mL throughout the treatment period (P < 0.0001), and subsided to pretreatment values 1–2 months after treatment cessation. CA 15‐3 values were found to be associated strongly with absolute neutrophil count, serum lactate dehydrogenase, and alkaline phosphatase. The median values and the kinetics of tumor markers did not differ over time in regard to hormonal receptor status and disease recurrence. CONCLUSIONS These data provide strong evidence that G‐CSF administration can induce elevation of CA 15‐3 and indicate that false‐positive results should be considered when evaluating CA 15‐3 in patients who are receiving G‐CSF. It is speculated that this phenomenon occurs through the induction of MUC1 antigen of unknown origin by G‐CSF. Experimental investigation of this clinical observation is warranted. Cancer 2001;91:909–17. © 2001 American Cancer Society.

show abstract

Preoperative CA 15‐3 concentrations predict outcome of patients with breast carcinoma

Cited by 18 publications

References 16 publications

Serum CEA and CA 15-3 as prognostic factors in primary breast cancer

Serum CEA and CA 15-3 as prognostic factors in primary breast cancer

Bone metastases from breast carcinoma: histopathological – radiological correlations and prognostic features

G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting

Contact Info

Product

Resources

About